Therefore, it is reasonable to speculate that LCP1 overactivated M1 hepatic macrophages and B lymphocytes by inhibiting Treg cells and regulating T effector cell functions, thereby contributing to the occurrence and progression of NAFLD/NASH. The gene discussed is LCP1; the disease is metabolic dysfunction-associated steatohepatitis.